The readers were blinded to each other's measurements and all clinical measures, including serum urate concentrations.
Laboratory measures including serum albumin, hemoglobin, iron status, serum chemistry, and parathyroid hormone (analyzed at one central laboratory) were collected as part of routine patient care and were retrieved through chart review.
Secondary outcome measures include serum antibody levels and activity of anti-FMP2.1 measured against recombinant 3D7 atA1 at baseline and at specified times during and after immunization.
Other measures include serum drug concentrations and self-reported measures of medication adherence (MARS) [ 24], and dispensing records to complement electronic medication-monitoring.
Outcome measures included serum PK and plasma free VEGF levels for ranibizumab, bevacizumab and aflibercept, following dose 1 and dose 3 at baseline, 3 h postinjection, and days 1, 3, 7 and 28.
Acute phase reactants measured included serum amyloid A, iron and fibrinogen, and the cytokines evaluated included interferon γ, tumor necrosis factor α, transforming growth factor (TGF -β, and inTGF -βkins 1β, 4, 5, 6, and 10.
Laboratory values measured included serum urea nitrogen and creatinine, urea and creatinine clearances (to calculate glomerular filtration rate), random urine albumin/creatinine and protein/creatinine ratios, 24-hour urine protein excretion, hemoglobin, glycated hemoglobin, lipid profile, and C-reactive protein (CRP).
Most laboratory values were measured monthly, including serum urea nitrogen, creatinine, serum albumin (Alb), BG, calcium, phosphate, and bicarbonate.
Most laboratory values were measured monthly, including serum urea, creatinine, albumin, calcium, phosphorus, bicarbonate, and total iron binding capacity.
Urinary TIMP-2 showed the highest AUC-ROC values for 7-day and in-hospital mortality among the measured biomarkers, including serum creatinine (Table 5).
Measures of iron metabolism including serum ferritin were not associated with combined microvascular or macrovascular end points.
